Table 4 In your experience, can the use of biologics in JDM patients reduce any of the following complications?
Calcinosis | 21/40 52.5% |
Muscle atrophy | 11/40 27.5% |
Lipodystrophy | 7/40 17.5% |
Osteonecrosis | 8/40 20% |
Ulcerative disease | 17/40 42.5% |
Internal organ damage/perforation/necrosis | 10/40 25% |
Other complications | 19/40 47.5% |